Approval · Notice of Compliance 2665 · 1998
FOSAMAX: Notice of Compliance 2665
Issued November 1, 1998
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2665
- Date
- November 1, 1998
- Company
- Merck Frosst Canada Inc.Kirkland, QC, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: treatment and prevention of glucocorticoid-induced osteoporosis in men and women
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FOSAMAX | Not yet assigned | — |
Medicinal ingredients
- ALENDRONATE SODIUM 5 MG per TAB
- ALENDRONATE SODIUM 10 MG per TAB